BLR-200

N/A

Report date: 2024/04/12 17:51:35

NME

Base Information

Drug NameBLR-200

Drug Alias Namesmall synthetic peptide based on a sequence found in the human endogenous protein, central coordination network protein 3 (Blr Bio)BLR-200

ClassificationSmall molecules > Synthetic peptide

Mechanisms of ActionFibroblast activation protein alpha antagonists

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Retroperitoneal FibrosisScleroderma, Systemic +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBlr Bio LLC

China Registration ClassN/A

Develop Information

Active CompaniesBlr Bio LLC

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Retroperitoneal FibrosisScleroderma, Systemic +[8]

Inactive IndicationsN/A

Other Information

ATC CodeN/A